CTRI/2023/01/049000招募中3 期
A Randomized, Double Blind, Multicenter, Parallel Group Study to Compare Efficacy, Safety, Immunogenicity, Pharmacokinetics and Pharmacodynamics of BP08 (Tocilizumab) and RoActemra® in patients with moderate to severe Rheumatoid Arthritis (RA) with inadequate response to Methotrexate - NA
CuraTeQ Biologics Private Ltd.0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Adult male or female patients of age 18 to 65 years (both inclusive)
- •Patients who are able to comply with study and follow-up procedures and provide written informed consent
- •Patients with diagnosis of Active Rheumatoid Arthritis as per the 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for RA score of =6 and has a disease duration of at least three months before randomization
- •Patients with Swollen Joint Count (SJC) =6 (66 joint count), and Tender Joint Count (TJC) =6 (68 joint count) at screening and randomization
- •Patients who are on NSAIDs, must be on a stable dose for at least 4 weeks prior to randomization.
- •Patient willing to receive oral folic acid (at least 5 mg/week or as per local practice) or folic acid (at least 1 mg/day or as per local practice) or equivalent during the trial period.
- •Men and women of childbearing potential must agree to use adequate birth control measures and continue such precautions for 6 months after receiving the last injection
排除标准
- •Patients with known or suspected allergy or hypersensitivity to Tocilizumab or formulation excipients
- •Patients with functional class IV disease as defined by the American College of Rheumatology (ACR) classification of functional status in RA
- •Patients with prior or current use of Tocilizumab
- •Patients with autoimmune disease other than Rheumatoid Arthritis like psoriatic arthritis (PsA), ankylosing spondylitis (AS), Crohn’s disease (CD), ulcerative colitis(UC) and plaque psoriasis.
- •Patients with active systemic bacterial, viral, fungal, mycobacterial, or other infections or on systemic antibiotics
- •Patients with known history of active tuberculosis and tests positive in QuantiFERON®-TB Gold In-Tube (QFT-G) and Mantoux test at screening
- •Patients with previous history of intestinal ulceration or diverticulitis.
- •Patient with history of and/or current medical condition, classed as clinically significant by the investigator, including cardiac, gastrointestinal, renal, hepatic, hematological (including pancytopenia, aplastic anemia or blood dyscrasia), metabolic (including known diabetes mellitus), neurologic or pulmonary diseases, or
- •psychiatric condition.
- •Patients with history of any form of cancer within the 10 years except skin cancer and cervical cancer in-situ
- •Patients with uncontrolled diabetes or hypertension
- •Patients with history of New York Heart Association class III/IV congestive heart
- •failure, unstable angina, cardiac arrythmias, or myocardial infarction within 6 months prior to randomization
- •Patients with history or signs of lymphoproliferative disease
- •Patients with significant systemic manifestations of rheumatoid arthritis such as vasculitis, interstitial lung disease, Pleuritis, pericarditis, Scleritis, Sjogren syndrome, Feltys syndrome and Lymphoma
- •Patients must not be on prescription herbal, homeopathic or ayurvedic medicines including massage/manipulation therapies for at least one month prior to randomization.
- •Patients with history of major surgery (including joint surgery) within 12 weeks prior to randomization
- •Patients with history of alcohol or drug abuse within 6 months prior to randomization
- •Patients with pregnancy or lactation at the time of screening
- •Patients with HIV infection, chronic hepatitis B, or hepatitis C infection
- •Patients with SARS CoV2 RT-PCR test positive at the time of screening
- •Patients with history of blood donation or blood loss of >300ml within 3 months prior to randomization
- •Patients with any medical, psychological, or social condition that may interfere with the patients participation in the study or evaluation of the study results
研究者
相似试验
已完成
不适用
To Evaluate the Efficacy and Safety of vitamin NMN in Middle Aged and Older Adults for Anti-aging and Work-Out EnhancerCTRI/2019/12/022514Effepharm Shanghai Co Ltd66
进行中（未招募）
1 期
Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbations in Subjects With Moderate to Very Severe COPDModerate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 18.0 Level: LLT Classification code 10010952 Term: COPD System Organ Class: 100000004855MedDRA version: 18.0 Level: LLT Classification code 10010953 Term: COPD exacerbation System Organ Class: 100000004855EUCTR2014-005671-92-ESPearl Therapeutics, Inc.8,000
进行中（未招募）
1 期
Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbations in Subjects With Moderate to Very Severe COPDEUCTR2014-005671-92-ITPEARL THERAPEUTICS, INC.8,588
进行中（未招募）
1 期
Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbations in Subjects With Moderate to Very Severe COPDEUCTR2014-005671-92-DEPearl Therapeutics, Inc.8,400
进行中（未招募）
1 期
Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbations in Subjects With Moderate to Very Severe COPDEUCTR2014-005671-92-SEPearl Therapeutics, Inc.8,588